BRISTOL-MYERS SQUIBB COMPANY (BMY) Cash and securities
- Total cash · latest quarter (USD): Value $11.07B; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $11.07B | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $8.72B + $2.35B ≈ $11.07B |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 8.72B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 2.35B USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Cash and current securities | 11.07B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Quarter-end shares | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $11.07B | (m) | $8.72B | $2.35B | (m) |
| 2026-03-31 | $10.49B | (m) | $9.57B | $912.00M | (m) |
| 2025-12-31 | $10.67B | (m) | $10.21B | $464.00M | (m) |
| 2025-09-30 | $16.50B | (m) | $15.73B | $776.00M | (m) |
| 2025-06-30 | $13.60B | (m) | $12.60B | $1.00B | (m) |
| 2025-03-31 | $11.78B | (m) | $10.88B | $907.00M | (m) |
| 2024-12-31 | $10.86B | (m) | $10.35B | $513.00M | (m) |
| 2024-09-30 | $8.09B | (m) | $7.89B | $204.00M | (m) |
| 2024-06-30 | $6.65B | (m) | $6.29B | $360.00M | (m) |
| 2024-03-31 | $9.67B | (m) | $9.33B | $340.00M | (m) |
| 2023-12-31 | $12.28B | (m) | $11.46B | $816.00M | (m) |
| 2023-09-30 | $7.68B | (m) | $7.51B | $171.00M | (m) |
| 2023-06-30 | $8.73B | (m) | $8.37B | $358.00M | (m) |
| 2023-03-31 | $9.27B | (m) | $8.99B | $274.00M | (m) |
| 2022-12-31 | $9.25B | (m) | $9.12B | $130.00M | (m) |
| 2022-09-30 | $9.03B | (m) | $7.73B | $1.29B | (m) |
| 2022-06-30 | $13.23B | (m) | $10.75B | $2.48B | (m) |
| 2022-03-31 | $14.97B | (m) | $12.37B | $2.60B | (m) |
| 2021-12-31 | $16.97B | (m) | $13.98B | $2.99B | (m) |
| 2021-09-30 | $15.66B | (m) | $13.54B | $2.12B | (m) |
| 2021-06-30 | $12.97B | (m) | $11.02B | $1.95B | (m) |
| 2021-03-31 | $12.93B | (m) | $10.98B | $1.95B | (m) |
| 2020-12-31 | $15.83B | (m) | $14.55B | $1.28B | (m) |
| 2020-09-30 | $21.16B | (m) | $19.43B | $1.72B | (m) |
| 2020-06-30 | $21.66B | (m) | $19.93B | $1.72B | (m) |
| 2020-03-31 | $18.32B | (m) | $15.82B | $2.50B | (m) |
| 2019-12-31 | $15.39B | (m) | $12.35B | $3.05B | (m) |
| 2019-09-30 | $32.54B | (m) | $30.49B | $2.05B | (m) |
| 2019-06-30 | $29.36B | (m) | $28.40B | $953.00M | (m) |
| 2019-03-31 | $8.76B | (m) | $7.33B | $1.43B | (m) |
| 2018-12-31 | $8.88B | (m) | $6.91B | $1.97B | (m) |
| 2018-09-30 | $6.83B | (m) | $5.41B | $1.42B | (m) |
| 2018-06-30 | $6.08B | (m) | $5.00B | $1.08B | (m) |
| 2018-03-31 | $6.77B | (m) | $5.34B | $1.43B | (m) |
| 2017-12-31 | $6.81B | (m) | $5.42B | $1.39B | (m) |
| 2017-09-30 | $7.12B | (m) | $4.64B | $2.48B | (m) |
| 2017-06-30 | $6.50B | (m) | $3.47B | $3.04B | (m) |
| 2017-03-31 | $6.11B | (m) | $3.91B | $2.20B | (m) |
| 2016-12-31 | $6.35B | (m) | $4.24B | $2.11B | (m) |
| 2016-09-30 | $5.56B | (m) | $3.43B | $2.13B | (m) |
| 2016-06-30 | $4.65B | (m) | $2.93B | $1.72B | (m) |
| 2016-03-31 | $4.31B | (m) | $2.64B | $1.66B | (m) |
| 2015-12-31 | $4.27B | (m) | $2.38B | $1.89B | (m) |
| 2015-09-30 | $5.41B | (m) | $3.98B | $1.44B | (m) |
| 2015-06-30 | $5.48B | (m) | $4.20B | $1.28B | (m) |
| 2015-03-31 | $7.61B | (m) | $6.29B | $1.31B | (m) |
| 2014-12-31 | $7.43B | (m) | $5.57B | $1.86B | (m) |
| 2014-09-30 | $7.22B | (m) | $4.85B | $2.37B | (m) |
| 2014-06-30 | $7.17B | (m) | $4.28B | $2.89B | (m) |
| 2014-03-31 | $7.06B | (m) | $5.22B | $1.83B | (m) |
| 2013-12-31 | $4.53B | (m) | $3.59B | $939.00M | (m) |
| 2013-09-30 | $2.72B | (m) | $1.77B | $951.00M | (m) |
| 2013-06-30 | $2.80B | (m) | $1.82B | $978.00M | (m) |
| 2013-03-31 | $2.53B | (m) | $1.35B | $1.18B | (m) |
| 2012-12-31 | $2.83B | (m) | $1.66B | $1.17B | (m) |
| 2012-09-30 | $2.93B | (m) | $1.50B | $1.43B | (m) |
| 2012-06-30 | $5.04B | (m) | $2.80B | $2.24B | (m) |
| 2012-03-31 | $5.03B | (m) | $2.31B | $2.72B | (m) |
| 2011-12-31 | $8.73B | (m) | $5.78B | $2.96B | (m) |
| 2011-09-30 | $8.19B | (m) | $4.47B | $3.72B | (m) |
| 2011-06-30 | $7.67B | (m) | $3.67B | $4.00B | (m) |
| 2011-03-31 | $6.79B | (m) | $3.40B | $3.39B | (m) |
| 2010-12-31 | $7.30B | (m) | $5.03B | $2.27B | (m) |
| 2010-09-30 | $8.36B | (m) | $7.58B | $778.00M | (m) |
| 2010-06-30 | $7.45B | (m) | $5.92B | $1.54B | (m) |
| 2010-03-31 | $6.78B | (m) | $5.13B | $1.64B | (m) |
| 2009-12-31 | $8.51B | (m) | $7.68B | $831.00M | (m) |
| 2009-09-30 | $6.67B | (m) | $6.37B | $302.00M | (m) |
| 2009-06-30 | $8.12B | (m) | $7.51B | $613.00M | (m) |
| 2009-03-31 | (m) | (m) | $7.83B | (m) | (m) |
| 2008-12-31 | $8.27B | (m) | $7.98B | $289.00M | (m) |
| 2008-09-30 | (m) | (m) | $7.17B | (m) | (m) |
| 2008-06-30 | (m) | (m) | $4.05B | (m) | (m) |
| 2007-12-31 | (m) | (m) | $1.80B | (m) | (m) |
| 2006-12-31 | (m) | (m) | $2.02B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |